Seizures as an Adverse Effect of Pregabalin Consumption: A Systematic Review
نویسندگان
1 Medical Toxicology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Immunology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Community Medicine Department, Mashhad University of Medical Sciences, Mashhad, Iran
4 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
5 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran,
6 Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
7 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
8 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
9 International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran
doi
10.34172/ahj.1527چکیده
Background: Pregabalin (PGB), a gabapantinoid drug, which is commonly prescribed by physicians and some patients abuse it,can lead to seizure. Pregabalin-induced seizures (PGBIS) and their risk factors were systematically reviewed.Methods: The databases were searched from January 1, 2011, to August 1, 2022. Studies that reported PGBIS were included. Therecords were assessed according to the PRISMA-P protocol.Results: From a total of 224 records, 11 studies were included, comprising four cross-sectional studies and seven case reports. Thedata from the cross-sectional studies were notably limited. Seven studies documented nine cases (five females and four males),with a median age of 51 years (ranging from 16 to 65). PGB was used for therapeutic purposes, abuse, and suicide attempts. Onecase had kidney dysfunction. A significant number of cases used PGB with other drugs. There was no difference between theingested dose of PGB in men (2700 and 4200 mg) and women (3000, 1200, 3825, and 1200 mg). All cases had normal renalfunction, except for one case.Conclusion: PGBIS is not common. However, it was reported for all purposes of PGB consumption. No specific risk factor forPGBIS was found. It was more commonly reported in females, patients who consumed high doses of PGB (>1200 mg), patientswho ingested multiple drugs, and patients with renal insufficiency. The dosages used for therapeutic purposes were much lowerthan in the other two groups
